|
⚲
|
| Message |
|---|
| Happy Holidays!! thanks for using AUM13F!! |
| Lynx1 Capital Management LP
✚
|
|
|---|---|
| CRD # | 310301 |
| SEC # | 801-127585 |
| CIK # | 0001910456 |
| AUM | $310.3 M (2025-06-23) |
| Employees | 5 (20% Investors, 0% Brokers) |
| Phone | 929-888-7476 |
| Address | D81 Calle C Dorado, PR 00646 |
| Source | [IAPD] [EDGAR] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Merus NV | 82.5 | ||
| GH Research PLC | 82.2 | ||
| Stoke Therapeutics Inc | 61.3 | ||
| Protagonist Therapeutics Inc | 40.5 | ||
| Cullinan Oncology Inc | 33.1 | ||
| Allogene Therapeutics Inc | 12.5 | ||
| TScan Therapeutics Inc | 11.4 | ||
| C4 Therapeutics Inc | 10.2 | ||
| Precision Biosciences Inc | 4.4 | ||
| Passage Bio Inc | 3.7 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold ($M) | AUM ($M) |
|---|---|---|---|---|
| PE | Lynx1 Opportunity Fund I LP | 2023-03-03 | 1.4 | |
| HF | Lynx1 Master Fund LP | [2021-10-13] | 176.2 | 278.4 |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 310.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 310.3 |
| By Discretionary | ||
| Discretionary | 5 | 310.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 310.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 310.3 | |
| United States Persons | 0.0 | |
| Total | 5 | 310.3 |
| Form D Directors | # Filings | # Firms | 2011 - 2025 |
|---|---|---|---|
| Weston Nichols | 5 | ||
| Lynx1 Capital Management LP | 2 | ||
| Lynx1 Fund GP LLC | 1 |
| EDGAR Form | CIK | 2011 - 2025 |
|---|---|---|
| 13F-HR | [0001910456] | |
| 3 | [0001910456] | |
| 4 | [0001910456] | |
| SC 13G | [0001910456] |
| Form 3/4/5 Subject | 2011 - 2025 |
|---|---|
| Nichols Weston | |
| Passage BIO, Inc. | |
| Lynx1 Capital Management LP | |
| TScan Therapeutics, Inc. |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Chalkstream Capital Group LP
✚
|
NY | 0.3 |
|
Coalescence Partners Investment Management LP
✚
|
NY | 0.3 |
|
Venor Capital Management LP
✚
|
NY | 0.3 |
|
Metavasi Capital LP
✚
|
NY | 0.3 |
|
Opus Investment Management LLC
✚
|
NY | 0.3 |
|
Beringea LLC
✚
|
MI | 0.3 |
|
Triangle Peak Partners LP
✚
|
CA | 0.3 |
|
Abry Partners LLC
✚
|
MA | 0.3 |
|
Chatham Capital Management LLC
✚
|
GA | 0.3 |
|
Resolute Capital Asset Partners LLC
✚
|
CO | 0.3 |